Medical/Pharmaceuticals News & Press Release Distribution

HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO

SYDNEY, Nov. 13, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment ofDamian Clarke-Bruce as Managing Director and CEO, effective13 November 2023. Outgoing CEO Bryce Carmine will remain active in the company, retaining his role as Cha...

2023-11-14 08:27 1056

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023

Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and sustained HBsAg loss rate New insight in utilizing BRII-179 to enriching patients with intrinsic humoral immune responses for higher HBsAg loss or HBV functional cure rates New data support ...

2023-11-14 06:40 1242

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023

Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and sustained HBsAg loss rate New insight in utilizing BRII-179 to enriching patients with intrinsic humoral immune responses for higher HBsAg loss or HBV functional cure rates New data support ...

2023-11-14 06:40 1409

Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®

MELBOURNE, Australia, Nov. 14, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. (QSAM) and its lead asset, CycloSam® (Samarium-153-DOTMP). QSAM is a United States (U.S.) based...

2023-11-14 06:33 1224

Rx-360 Releases Two New Publications in Support of the Pharmaceutical Industry and Patient Safety

PHILADELPHIA, Nov. 14, 2023 /PRNewswire/ -- Rx-360 is pleased to announce that the consortium membership led by key members of the Supplier Quality Working Group have released two new papers this week to help drive best practices in pharmaceutical supply chain integrity and patient safety. The t...

2023-11-14 03:00 1357

SCG Cell Therapy Announces Late-Breaking Clinical Data at AASLD Showing SCG101 Improved Tumor Reponses and Achieved Sustained Antiviral Activates in Patients with Advanced HBV-related Hepatocellular Carcinoma

SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced late-breaking clinical data from its first-in-class autologous hepatitis B virus ...

2023-11-14 02:00 2334

More than two in three people with diabetes already have complications at diagnosis, International Diabetes Federation study finds

Global research from the International Diabetes Federation reveals that 72% of people living with diabetes only received their diagnosis because they had at least one of the related complications – such as loss of vision, nerve damage or heart disease. BRUSSELS, Nov. 14, 2023 /PRNewswire/ -- Sev...

2023-11-14 00:36 1444

Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries

Program aims to address key barriers to genomic sequencing in-country SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to p...

2023-11-13 22:15 1462

OliPass Discloses Painful but Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002

SEOUL, South Korea, Nov. 13, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed uncanny clinical findings from a multi-center Phase 2a trial with Nav1.7 selective OLP-1002 in osteoarthritis (OA) patients with moderate to severe pain inAustralia with Novotech...

2023-11-13 22:00 1129

Datasea Reports First Quarter Fiscal Year 2024 Financial Results and Operations Update

BEIJING, Nov. 13, 2023 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a global technology company that develops and provides products utilizing intelligent acoustics including ultrasound, infrasound and directional sound, and provides 5G messaging, today announced its f...

2023-11-13 21:30 1936

AnchorDx, DiaCarta Partner Developing Novel Cancer Screening Tests

GUANGZHOU, China, Nov. 13, 2023 /PRNewswire/ -- AnchorDx, a leading diagnostics company developing cancer early detection tests, announced today that it has entered into a long-term collaboration with DiaCarta, a precision molecular diagnostics company and developer of novel oncology and infectio...

2023-11-13 21:00 1039

AnchorDx, DiaCarta Partner Developing Novel Cancer Screening Tests

GUANGZHOU, China, Nov. 13, 2023 /PRNewswire/ -- AnchorDx, a leading diagnostics company developing cancer early detection tests, announced today that it has entered into a long-term collaboration with DiaCarta, a precision molecular diagnostics company and developer of novel oncology and infectio...

2023-11-13 21:00 1288

PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE

* PYC has developed a new drug candidate for the >5 million people worldwide [1] with Polycystic Kidney Disease (PKD) * This drug candidate has demonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due to PKD[2] * PKD is a life-changing diseas...

2023-11-13 21:00 1166

PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition ZUG, Switzerland and PARIS, Nov. 13, 2023 /PRNewswire/ -- Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical c...

2023-11-13 20:20 1114

TB Alliance Applauds Macleods' Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen

Macleods becomes second pharmaceutical manufacturer to bring pretomanid supply to market and first since the World Health Organization issued updated DR-TB treatment guidelines NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Indian pharmaceutical company Macleods has become the second manufacturer to la...

2023-11-13 18:31 1131

BizLink once again proves its ability to innovate in healthcare robotics

At the MEDICA show in Duesseldorf, BizLink presents its new PULSAR platform, an ultrasafe and precise range of robotic arms for medical para-medical applications. CHARTRES, France, Nov. 13, 2023 /PRNewswire/ -- BizLink, a leading global interconnect solutions provider, announced the introduction...

2023-11-13 17:53 1361

BizLink once again proves its ability to innovate in healthcare robotics

Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery

MELBOURNE, Australia and PARIS, Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) andParis-based Mauna Kea Technologies (Euronext Growth: ALMKT,Mauna Kea), today announce an expansion of the IRiS (Imaging and Robotics in Surgery) Alliance[1] through a stra...

2023-11-13 16:27 1223

Nona Biosciences Announces Strategic Collaboration with GeneQuantum Healthcare to Empower Early Discovery of Next-Generation Bioconjugates

CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, today announced that it has entered into a strategic collaboration with GeneQuantum Healthcare to advance the early discovery of next-gener...

2023-11-13 16:04 1150

Fundiin partners with Pharmacity to launch BNPL at a thousand drugstores in Vietnam

Fundiin and Pharmacity have forged the first-ever Buy Now Pay Later (BNPL) partnership in the pharmacy retail sector, with Fundiin being the most popular BNPL provider inVietnam and Pharmacity emerging as the regional leading drugstore chain. HO CHI MINH CITY, Vietnam, Nov. 13, 2023 /PRNewswire/...

2023-11-13 14:58 1922

Fundiin partners with Pharmacity to launch BNPL at a thousand drugstores in Vietnam

USgHIFUa: a listed Operation at public hospitals

and available at Cornwall Medical in the private sector HONG KONG, Nov. 13, 2023 /PRNewswire/ -- "High intensity focused ultrasound ablation of lesion of uterus using ultrasound guidance" has been included as an "Operation" categorized under "INTERMEDIATEII" on the "List of Private Services"[i] ...

2023-11-13 09:00 1142